ICU Medical, Inc.

How big is ICU Medical, Inc.?

As of Jun 18, ICU Medical, Inc. has a market capitalization of 3,198.84 million, with net sales of 2,417.10 million and a net profit of -93.70 million over the latest four quarters.

Market Cap: As of Jun 18, ICU Medical, Inc. has a market capitalization of 3,198.84 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ICU Medical, Inc. reported net sales of 2,417.10 million and a net profit of -93.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,965.23 million and total assets of 4,203.93 million.

What does ICU Medical, Inc. do?

ICU Medical, Inc. develops and sells medical devices for infusion therapy, oncology, and critical care, with recent net sales of $604 million and a market cap of approximately $3.2 billion. The company reported a net profit of -$15 million for the most recent quarter.

Overview: <BR>ICU Medical, Inc. is engaged in the development, manufacture, and sales of medical devices used in infusion therapy, oncology, and critical care applications, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 604 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,198.84 Million (Small Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 0.63 <BR>Return on Equity: -1.96% <BR>Price to Book: 1.61<BR><BR>Contact Details: <BR>Address: 951 Calle Amanecer, SAN CLEMENTE CA: 92673 <BR>Tel: ['1 949 3662183', '1 646 2771254'] <BR>Fax: 1 949 3668368 <BR>Website: http://www.icumed.com/

Should I buy, sell or hold ICU Medical, Inc.?

Who are in the management team of ICU Medical, Inc.?

As of March 2022, the management team of ICU Medical, Inc. includes Chairman and CEO Vivek Jain, Lead Independent Director David Greenberg, Directors George Lopez, Donald Abbey, Elisha Finney, and David Hoffmeister. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of ICU Medical, Inc. includes the following individuals:<BR><BR>- Mr. Vivek Jain, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. David Greenberg, who is the Lead Independent Director.<BR>- Dr. George Lopez, who is a Director.<BR>- Mr. Donald Abbey, who is an Independent Director.<BR>- Ms. Elisha Finney, who is also an Independent Director.<BR>- Mr. David Hoffmeister, who serves as an Independent Director. <BR><BR>This team plays a crucial role in overseeing the company's strategic direction and governance.

Is ICU Medical, Inc. overvalued or undervalued?

As of November 7, 2022, ICU Medical, Inc. is considered overvalued and risky due to its high EV to EBITDA ratio of 13.71, low ROCE of 3.62%, and poor stock performance compared to peers and the S&P 500.

As of 7 November 2022, the valuation grade for ICU Medical, Inc. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its high EV to EBITDA ratio of 13.71 and a Price to Book Value of 1.65, which suggests that investors are paying a premium relative to the company's assets. Additionally, the latest ROCE stands at a mere 3.62%, highlighting inefficiencies in generating returns from capital employed.<BR><BR>When compared to peers, ICU Medical's valuation metrics are concerning; for instance, Globus Medical, Inc. has a much lower EV to EBITDA of 12.32 and a more favorable P/E ratio of 18.37, while Sanmina Corp. shows a strong EV to EBITDA of 22.21. The stock has underperformed against the S&P 500, with a year-to-date return of -14.27% compared to the index's 12.22%, and a staggering 5-year return of -32.99% versus 96.61% for the S&P 500. This performance reinforces the notion that ICU Medical is currently overvalued in the market.

Is ICU Medical, Inc. technically bullish or bearish?

As of October 3, 2025, ICU Medical, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -21.78% compared to the index's 14.18%.

As of 3 October 2025, the technical trend for ICU Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating mild bullishness, while the monthly MACD remains bearish. The daily moving averages are bearish, and Bollinger Bands show a bearish trend on the weekly and mildly bearish on the monthly. The KST is mildly bullish on the weekly but mildly bearish on the monthly. There are no clear trends indicated by Dow Theory or OBV.<BR><BR>In terms of performance, ICU Medical has underperformed the S&P 500 across multiple periods, with a year-to-date return of -21.78% compared to the S&P 500's 14.18%, and a one-year return of -32.27% versus 17.82% for the index.